Study of the Incidence of Jarisch-Herxheimer Reaction in Leptospirosis Patients in New Caledonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-23

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to estimate the incidence of Jarisch-Herxheimer Reactions (JHR) during antibiotic treatment of human leptospirosis cases in New Caledonia.

Participants are patients managed in one of the 5 centres participating in the study, in whom a clinical doctor suspected leptospirosis. The average number of leptospirosis cases in New Caledonia is 89 per year. Given the proportion of positive diagnostic tests (approximately 10%) 900 inclusions are planned for this study.

Patients are included at the time of the consultation during which leptospirosis is suspected, before the initiation of their antibiotic therapy and independently of the clinical form they presented.

Data (socio-demographic and health) and blood samples will be collected at 3 points in the study: at baseline, three hours and six hours after antibiotic treatment.

This study will allow better management of patients with leptospirosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Research for Angiostrongylus Cantonensis and Costaricensis in French West Indies and French Guiana

NCT03378882

Angiostrongylosis Hypereosinophilia

UNKNOWN

Retrospective Study of Clinical Practice and Management of Imported Schistosomiasis in France

NCT04810741

Schistosomiasis

COMPLETED

Validation of INSPiRED Innovative Smart Diagnostic Devices for the Detection of Parasites Infections.

NCT04505046

Testing Performance Specificity +1 more

UNKNOWN

Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis

NCT05466630

Human African Trypanosomiasis Sleeping Sickness Trypanosoma Brucei Gambiense; Infection +1 more

COMPLETED NA

Spontaneous Antigenemia in Loiasis

NCT04258670

Loiasis Lymphatic Filariasis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the study is to estimate the incidence of Jarisch-Herxheimer Reactions (JHR) during antibiotic treatment of human leptospirosis cases in New Caledonia.

Secondary objectives of the study are to describe the JHR during leptospirosis (describe clinical, haemodynamic and cytokine response parameters), to describe the effects of the progressive introduction of antibiotic (ATB) for the treatment of leptospirosis and to harmonise management practices for patients with leptospirosis in NC.

Participants are patients managed in one of the 5 centres participating in the study, in whom a clinical doctor suspected leptospirosis. The average number of leptospirosis cases in New Caledonia (NC) is 89 per year. Given the proportion of positive diagnostic tests (approximately 10%) 900 inclusions are planned for this study.

Patients are included at the time of the consultation during which leptospirosis is suspected, before the initiation of their antibiotic therapy and independently of the clinical form they presented.

Blood samples will be collected at 3 points in the study: at baseline, three hours and six hours after antibiotic treatment.

Data will be collected at 4 points in the study: at baseline, three hours, six hours after antibiotic treatment and one day after treatment introduction (last point by phone call).

The data obtained will allow us to describe for the first time, in a prospective study, the JHR associated with leptospirosis in a significant number of patients.

The data obtained will also help to describe the impact of a therapeutic strategy on the evolution of the disease, which has not yet been evaluated. This study also aims to help harmonise the management of patients with leptospirosis in NC.

This study will allow better management of patients with leptospirosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leptospirosis Jarisch Herxheimer Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients diagnosed by a clinician who suspects leptospirosis

Group Type OTHER

Blood collection

Intervention Type OTHER

Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment

Data collection

Intervention Type OTHER

collection of socio-demographic, clinical and biological data.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood collection

Blood samples (8ml) at three times of the study: at baseline, 3 hours and 6 hours after treatment

Intervention Type OTHER

Data collection

collection of socio-demographic, clinical and biological data.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be over 18 years of age (at the time of inclusion);
* Be suspected of developing leptospirosis by the clinician in one of the 5 participating centres
* Have been informed of the use of their samples for non-therapeutic scientific research purposes by a note and information sheet established by the Institut Pasteur of New Caledonia (IPNC) and the Institut Pasteur Paris (IPP), provided and explained by the inclusion centre.
* Have expressed their oral consent to participate in this research project

* Under 18 years of age
* Have not given oral consent to participate
* Have a chronic inflammatory disease.
* Having concomitant antibiotic and/or anti-inflammatory treatment or medical management incompatible with the purpose of the study,
* Pregnant or breastfeeding women.

Exclusion Criteria

\- Leptospirosis diagnostic is not confirmed by molecular biology. Complete destruction of the corresponding samples will be ensured. Clinical data and biological analyses will also be removed from the data associated with the research.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No